EuroBiotech: More Articles of Note

newspapers
(Pixabay)

> Hookipa Pharma priced its IPO at $14 (€12) a share, setting it up to raise $84 million. The money will enable Hookipa to take a cytomegalovirus infection candidate through phase 2. Release 

> Affimed provided the FDA with information it hopes will lead to the lifting of the clinical hold on AFM11. The German biotech expects to receive an update from the FDA in the second quarter. Statement 

> Cassiopea posted 12-month data from a phase 2 trial of androgenic alopecia treatment Breezula. The trial met one of its two co-primary endpoints. Release 

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

> Silence Therapeutics named Giles Campion as head of R&D and chief medical officer. Campion was CMO at DMD biotech Prosensa at the time of its acquisition by BioMarin Pharmaceutical. Statement

> GenSight Biologics posted 72-week data from a Leber hereditary optic neuropathy gene therapy phase 3 trial. Release 

> Mereo BioPharma revealed it has wrapped up an end-of-phase 2 meeting with the FDA. The company thinks the regulatory progress will help with partnering discussions about chronic obstructive pulmonary disease prospect acumapimod. Statement 

Suggested Articles

In this week's EuroBiotech Report, AstraZeneca plans 2020 lupus filing, Roche's SMA trial hits endpoint and Kiadis cuts staff in R&D pivot.

In our EuroBiotech roundup this week, NEC and Vaximm ink cancer vaccine pact, Compugen posts cancer data and Lunac raises cash.

Biotech venture fund ATAI Life Sciences has partnered with artificial intelligence drug discovery specialist Cyclica to form a new JV.